fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg. - LARVOL DELTA

Clinical efficacy of Chaipu Decoction combined with Seretide in the treatment of bronchial asthma and its impact on TNF-α and CD4+/CD8. (PubMed, Sci Rep) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • CD4 • TNFA

Fluticasone- vs Budesonide-Based Dual Therapy for COPD. (PubMed, JAMA Netw Open) - "In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate-vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate-salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Single vs Dual Lactose-Polyethylene Glycol 3000 Microcarrier Systems for Pulmonary Salmeterol and Fluticasone Targeted Delivery. (PubMed, Drug Des Devel Ther) - "Dual-microcarrier increased pulmonary drug retention with a marginal rise in systemic drug levels and reduced inflammatory lymphocytes/eosinophils/neutrophils infiltration, IL-4/5/9/13 release, mucus production, and bronchoconstriction. Dual-microcarrier is more efficient than single-microcarrier in pulmonary SX/FP delivery."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL4

CLI-05993AA5-06: A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) with a commercial drug (Seretide Evohaler) in adolescent subjects with treated uncontrolled asthma (clinicaltrialsregister.eu) - P2/3 | N=147 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.

New P2/3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand. (PubMed, BMJ Open Respir Res) - "Our study indicated that SITTs are not cost-effective at the current price compared with the current MITT for COPD treatment. However, FF/UMEC/VI could be a promising option, with an approximately 30% price reduction."

Clinical • HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial. (PubMed, Thorax) - P3 | "Our findings suggest potent LAMA and ICS treatment withdrawal effects on exacerbations, highlighting the importance of treatment adherence and accounting for withdrawal effects in clinical trials."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Clinician Views on Inhaler Substitution in the Veterans Health Administration. (PubMed, Chest) - "VHA clinicians reported predominantly negative perceptions of the 2021 inhaler formulary change, underscoring the importance of timely clinician communication, patient education, and specialty engagement in future formulary transitions."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (clinicaltrials.gov) - P3 | N=304 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Feb 2029 ➔ Dec 2029 | Trial primary completion date: Mar 2026 ➔ Dec 2028

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Case Report of a Refractory Bronchial Asthma (APSR 2025) - "Case Report : A 50-year-old hypertensive woman presented with recurrent dyspnea and wheezing refractory to inhaled salmeterol/fluticasone over 12 months...Subcutaneous mepolizumab (300 mg/month) combined with low-dose prednisone (7.5 mg/day) achieved sustained remission (eosinophils < 0.5×10 9 /L) over 6-month follow-up. Discussion : EGPA is a rare but serious autoimmune disease with significant current challenges in disease management, low diagnostic rates, and a high disease burden; In patients with severe asthma who have elevated EOS with sinusitis or nasal polyps, physicians need to be alert to the possibility of EGPA, with attention to evaluating extrapulmonary organs and pulmonary imaging manifestations; The prognosis of EGPA depends on whether it is diagnosed early and treated in a standardized manner. Early diagnosis and treatment can improve the prognosis and the quality of patients' survival."

Case report • Clinical • Asthma • Cardiovascular • Eosinophilia • Eosinophilic Granulomatosis With Polyangiitis • Hypereosinophilic Syndrome • Immunology • Inflammation • Langerhans Cell Histiocytosis • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Sinusitis • Vasculitis

A Curious Case Of Severe Asthma (ACAAI 2025) - "Despite compliance with Fluticasone propionate/Salmeterol 500/50 mcg, Tiotoprium 2.5 mcg, she was using her Levalbuterol MDI daily...Six weeks later, she reported that her exercise tolerance and dyspnea were significantly improved after a week of treatment with Apixaban. She had not needed her Levalbuterol inhaler since her last appointment. Discussion It is important to consider alternative diagnoses and a patient’s medical history when asthma is not well-controlled, especially when one has unique symptoms and is not responding to traditional asthma medications."

Clinical • Allergic Rhinitis • Asthma • Cardiovascular • Immunology • Inflammation • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Relative Bioavailability of Inhaled Fluticasone Propionate and Salmeterol - is Population Pharmacokinetic Modelling a Relevant Alternative to a Non-Compartmental Approach? (PubMed, Drug Des Devel Ther) - "Model- and NCA-based approaches to assess bioequivalence were consistent. However, a frequentist parametric approach that fully utilizes the population analysis potential and mechanistically predicts regional pulmonary deposition of FP and SALM would require a demographically more heterogenous data set and analysis including additional outcomes of parenteral and oral administration to discriminate presystemic from systemic disposition."

Clinical • Journal • PK/PD data

UNVEILING THE ENIGMATIC CULPRIT: AMYOPATHIC DERMATOMYOSITIS IN RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE (CHEST 2025) - "Despite using steroids, cyclophosphamide, tacrolimus, intravenous immunoglobulins, and broad-spectrum antimicrobials patient's respiratory failure rapidly progressed resulting in his death.Patient B was a 44-year-old female on rituximab for neuromyelitis optica spectrum disorder...Despite initial treatment with fluticasone-salmeterol and oral prednisone her dyspnea worsened, and a repeat chest CT showed progression in her ground-glass opacities with septal thickening...Despite the success rates associated with the combined use of tacrolimus, cyclophosphamide and steroids, some case reports reported the use of mycophenolate mofetil as a single agent, which has not yielded comparable outcomes... Given the prognosis and rapid clinical decline in patients with positive anti-MDA5 antibodies, initial testing with a full ILD panel for new onset interstitial lung disease should be considered. Early detection of this antibody will trigger aggressive treatment early in the..."

CNS Disorders • Cough • Dermatomyositis • Immunology • Infectious Disease • Interstitial Lung Disease • Melanoma • Meningococcal Infections • Myositis • Neuromyelitis Optica Spectrum Disorder • Pneumonia • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Rheumatology • Solid Tumor • IFIH1

Is dual bronchodilation a cost-effective alternative to ICS/LABA in COPD? A Colombian healthcare system evaluation. (PubMed, Expert Rev Respir Med) - "Although ICS/LABA combinations like fluticasone/salmeterol (FSC) are widely used, dual bronchodilation with umeclidinium/vilanterol (UMEC/VI) may offer clinical and economic advantages. UMEC/VI yielded 8.74 additional QALYs compared to FSC, with an incremental cost of $7,039 USD, resulting in an ICER of $805 per QALY - well below Colombia's WTP threshold of $5,180. Sensitivity analyses confirmed model robustness; UMEC/VI remained cost-effective in 64% of simulations."

HEOR • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacoeconomic evaluation of ICS-LABA therapy in pediatric asthma: a cost-effectiveness and cost-utility analysis. (PubMed, Front Pharmacol) - "Group A consisted of subgroups A1 (salmeterol-fluticasone) and A2 (budesonide-formoterol), while Group B included subgroups B1 (two inhaled medications) and B2 (three inhaled medications)...For children with more severe asthma, multiple ICS-LABA therapies, particularly triple therapy, offer better cost-effectiveness in the long term, while single-inhaler therapy remains economically viable for milder conditions. These findings support a stratified, individualized treatment approach and provide evidence for optimizing healthcare resource allocation in pediatric asthma management."

HEOR • Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Adverse reactions to biotechnological agents targeting IL-5 (PubMed, Rev Alerg Mex) - "A percentage of patients with asthma presented with severe symptoms, 80% with an eosinophilic phenotype, associated with difficult control and increased exacerbations. Monoclonal antibodies are indicated in these patients. Benralizumab, which targets IL-5Rα, induces eosinophil depletion through antibody-mediated cytotoxicity. Several studies (MELTEMI) have been conducted to evaluate the safety of long-term use. The most common non-serious adverse effects include upper respiratory tract viral infections (47.3%), while less common adverse effects are headache and arthralgia, which account for 20.9% and 6.4%. Biotechnological agents reduce exacerbations, reduce corticosteroid use, and improve control and quality of life. However, they are not exempt from adverse effects, and even the less common ones should be identified to assess continued treatment."

Journal • Allergic Rhinitis • Asthma • Immunology • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain • Pulmonary Disease • Respiratory Diseases • IL5

Comparative Effectiveness of Fixed-Dose ICS/LABA Therapy in Adult Patients with Asthma. (PubMed, Ann Allergy Asthma Immunol) - "The findings suggest that fluticasone furoate/vilanterol may offer a potential advantage for asthma management compared to other fixed-dose ICS/LABA combinations."

HEOR • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The Impact of Salmeterol and Fluticasone on Clinical Outcomes and Inflammatory Mediators in Asthma in vivo (ERS 2025) - "Only combined salmeterol/fluticasone improved lung function and suppressed cAMP-induced inflammatory mediators, strongly advocating use of ICS with β2 agonists in the management of asthma."

Clinical data • Preclinical • Asthma • Immunology • Respiratory Diseases • BDNF • IL17A • IL33 • IL6 • MMP10 • MMP2 • MUC2 • MUC5AC • MUC5B • MUC7 • TGFB1 • TGFB2

Prevalence of Preserve Ratio Impaired Spirometry (PRISm) in a tertiary government hospital in the Philippines, Its association with gender, smoking history and body mass index and the incidence of airflow limitation after a 3 year follow up (ERS 2025) - "Combination inhalers, including salmeterol-fluticasone (22.4%) and budesonide-formoterol (18.8%), were commonly used... The study highlights PRISm's prevalence and diverse outcomes. While no significant links to demographic or clinical factors were found. PRISm poses health risks."

Clinical • Pulmonary Disease • Respiratory Diseases

General physicians' experience and perception of symptoms control in patients of asthma changed to branded generic formulation of Salmeterol/Fluticasone in Spain: The ORIGEN study (ERS 2025) - "In this study, GPs from Spain, experienced good asthma control in their patients after switching to branded generic formulation of Salmeterol/Fluticasone."

Clinical • Asthma • Immunology • Respiratory Diseases

Effectiveness Salmeterol-Fluticasone and Indacaterol on FEV1/FVC Post-Tuberculosis Patient at dr. H. Abdul Moeloek Hospital Lampung Province Indonesia (ERS 2025) - "Salmeterol-fluticasone improves lung function better compared to Indacaterol. Conclusions Salmeterol-fluticasone is effective in improving post-tuberculosis who experience a decreased in FEV1/FVC."

Clinical • Infectious Disease • Respiratory Diseases • Tuberculosis

Cost-Utility of Fluticasone Propionate/Salmeterol and Fluticasone Propionate Monotherapy in Step-Up Treatment of Childhood Asthma. (PubMed, Pediatr Pulmonol) - "This study's findings are aligned with previous evidence on the economic value of ICS/LABA combinations, which found similar cost-effectiveness ratios for ICS/LABA therapies within accepted thresholds. Our probabilistic perspective supports FSC's potential as a feasible option in clinical practice for achieving better asthma control in children."

HEOR • Journal • Monotherapy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe chronic obstructive pulmonary disease: A randomized trial (MUSIC). (PubMed, Eur Respir J) - "Fluticasone/salmeterol 500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Secondary Adrenal Insufficiency due to Inhaled Fluticasone Use Alone (ENDO 2025) - "Her life-long history of asthma was controlled on daily fluticasone propionate/salmeterol and albuterol as needed. She also suffered from intermittent asthma flares which required steroid courses with most recent prednisone course a year prior to presentation...She was recommended to start on hydrocortisone replacement however instead, she slowly tapered off her inhaled steroid over the course of three months...It has been better recognized that concomitant use of CYP3A4 inhibitor can cause AI such as seen in ritonavir with inhaled fluticasone or itraconazole and inhaled budesonide...Through this report, we aim to raise awareness about the potential risk of SAI associated with inhaled steroid use alone. We would like to emphasize the importance of careful clinical evaluation in those receiving long-term corticosteroid therapy regardless of formulation, and prompt recognition and treatment to prevent adrenal crisis and improve patient outcomes."

Asthma • Endocrine Disorders • Fatigue • Immunology • Nephrology • Renal Disease • Respiratory Diseases

Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler. (PubMed, JAMA Intern Med) - "Rescue medication use (albuterol and prednisone fills), emergency department visits, and hospitalizations (all-cause, respiratory-related, and pneumonia-specific) were assessed. In the cohort study of 258 557 patients (mean [SD] age, 68.9 [11.3] years; 94% male), those who switched to a fluticasone-salmeterol dry-powder inhaler had no difference in mortality (1.89% vs 1.90%; adjusted absolute difference, -0.01 percentage points [95% CI, -0.12 to 0.10 percentage points]) but had increases in all-cause hospitalizations (16.14% vs 15.64%; adjusted absolute difference, 0.49 percentage points [95% CI, 0.21-0.78 percentage points]), respiratory-related hospitalizations (3.15% vs 2.74%; adjusted absolute difference, 0.41 percentage points [95% CI, 0.27-0.55 percentage points]), and pneumonia-related hospitalizations (1.15% vs 1.03%; adjusted absolute difference, 0.12 percentage points [95% CI, 0.04-0.21 percentage points]) at 180 days after the switch compared with matched..."

Journal • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Robotic tracheobronchoplasty from the perspective of anesthetic assistance: a case report (Euroanaesthesia 2025) - "History of severe, refractory asthma, complicated by tracheomalacia, using Beclometasone + Formoterol + Glycopyrronium and Salmeterol + Fluticasone.3 Salbutamol puffs were administered just before anesthetic induction, which was performed with Fentanyl, Propofol and Rocuronium...Maintenance was achieved with continuous infusion of Propofol, Remifentanil and Rocuronium. Adjuvants included Ketamine, Methadone, Magnesium Sulfate, Lidocaine and Dexmedetomidine. Tranexamic acid was administered to reduce risk of bleeding.During the surgical procedure, selective ventilation and periods of apnea were required for tracheal suturing...She was discharged 7 days later without complications. Robotic-assisted tracheobronchoplasty has been first described in the last 10 years1, and anesthesia for this procedure presents additional challenges with the use of the robotic system, the need for immobility and intermittent ventilatory maneuvers. This case demonstrates a successful approach..."

Case report • Clinical • Anesthesia • Asthma • Immunology • Respiratory Diseases